Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Accumulated Expenses (2023 - 2025)

Historic Accumulated Expenses for Artiva Biotherapeutics (ARTV) over the last 3 years, with Q3 2025 value amounting to $7.0 million.

  • Artiva Biotherapeutics' Accumulated Expenses fell 1579.58% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year decrease of 1579.58%. This contributed to the annual value of $7.4 million for FY2024, which is 779.59% down from last year.
  • As of Q3 2025, Artiva Biotherapeutics' Accumulated Expenses stood at $7.0 million, which was down 1579.58% from $5.8 million recorded in Q2 2025.
  • In the past 5 years, Artiva Biotherapeutics' Accumulated Expenses registered a high of $8.3 million during Q3 2024, and its lowest value of $5.8 million during Q2 2025.
  • Its 3-year average for Accumulated Expenses is $7.0 million, with a median of $7.0 million in 2025.
  • Data for Artiva Biotherapeutics' Accumulated Expenses shows a peak YoY increase of 605.09% (in 2025) and a maximum YoY decrease of 1579.58% (in 2025) over the last 5 years.
  • Over the past 3 years, Artiva Biotherapeutics' Accumulated Expenses (Quarter) stood at $8.0 million in 2023, then decreased by 7.8% to $7.4 million in 2024, then fell by 4.95% to $7.0 million in 2025.
  • Its Accumulated Expenses stands at $7.0 million for Q3 2025, versus $5.8 million for Q2 2025 and $6.4 million for Q1 2025.